Despite osimertinib being the treatment of choice for EGFR T790M‐positive NSCLC, the pattern of osimertinib resistance and the appropriate subsequent treatment guidelines are limited in the real‐world setting.14, 15, 16, 17, 18. This evidence concerns the gene EGFR and non-small cell lung carcinoma.